Frontiers in Oncology (Aug 2023)
Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
- Daling Dong,
- Shixin Zhang,
- Bin Jiang,
- Wei Wei,
- Chao Wang,
- Qian Yang,
- Tingzhi Yan,
- Min Chen,
- Liken Zheng,
- Weikang Shao,
- Gang Xiong
Affiliations
- Daling Dong
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- Shixin Zhang
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- Bin Jiang
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- Wei Wei
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- Chao Wang
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- Qian Yang
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- Tingzhi Yan
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- Min Chen
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- Liken Zheng
- Genecast Biotechnology Co., Ltd., Wuxi, China
- Weikang Shao
- Genecast Biotechnology Co., Ltd., Wuxi, China
- Gang Xiong
- Department of Cardiothoracic Surgery, Guiqian International Hospital, Guiyang, China
- DOI
- https://doi.org/10.3389/fonc.2023.1275851
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords
- molecular residual disease
- liquid biopsy
- non-small cell lung cancer
- adjuvant therapy
- clinicopathological features
- immune markers
